Our veterinary vaccine production plant GMP engineering turnkey solution delivers integrated, biosafety-aligned manufacturing infrastructure purpose-built for animal health immunologicals, including live attenuated, inactivated, subunit and vector-based vaccine campaigns. Distinct from human biopharma facilities, the design framework embeds layered biocontainment controls alongside GMP contamination mitigation principles, addressing the unique hazards of handling infectious seed stocks, bulk viral harvests and adjuvanted formulation streams. We orchestrate the full facility master plan to segregate high-risk seed expansion, virus propagation, inactivation, downstream purification, aseptic fill-finish, QC laboratories and waste decontamination zones, implementing dedicated personnel, material and air flow regimes to eliminate cross-contamination and cross-over risks across multi-product pipelines. The solution is engineered to align with WOAH, EU GMP Annex 5 and regional veterinary regulatory expectations, supporting clients advancing from pilot vaccine development to licensed commercial batch release for livestock, poultry and companion animal markets.
The core engineering architecture integrates hygienic bioprocess trains, classified cleanroom suites, biocontainment HVAC, validated decontamination systems and harmonised automation platforms into a cohesive EPC delivery scope. Upstream seed train and bioreactor skids, inactivation vessels, TFF and chromatography downstream modules, buffer preparation systems and aseptic filling lines are specified with ASME BPE wetted construction, supported by validated CIP/SIP sequences where applicable. Critical biosafety features include pressure cascade control, HEPA filtration on supply and exhaust, effluent kill systems, and validated fumigation routines for containment zones, paired with environmental monitoring, particulate and microbial trending systems linked to plant DCS and SCADA controls. All P&IDs, utility schematics, cleanroom layouts and control narratives are developed with full traceability, generating the complete validation and qualification dataset required for regulatory inspection, licensing and ongoing site audit readiness.
This turnkey veterinary vaccine plant model de-risks capital delivery and creates durable operational advantages for animal health manufacturers. The unified single-point accountability of turnkey execution eliminates interface friction between architects, cleanroom contractors, process equipment vendors and automation suppliers, compressing overall project schedule and reducing coordination gaps that commonly delay vaccine plant commissioning. Segregated containment zoning enables flexible campaign scheduling for multiple vaccine serotypes without costly full-site sanitisation between batches, while scalable modular skid design supports phased capacity expansion as market demand grows. Built-in waste inactivation and air treatment systems also mitigate environmental release risks, protecting site biosecurity and simplifying compliance with local environmental and biosecurity authority requirements across global operating jurisdictions.
We manage the full project lifecycle from URS development, conceptual layout and detailed engineering through procurement, fabrication, construction, FAT/SAT, installation, commissioning, qualification and regulatory submission support. Our multi-disciplinary engineering team combines deep expertise in bioprocessing, biosafety containment, cleanroom HVAC and veterinary GMP regulation, working collaboratively with your R&D, production, quality and regulatory teams to align the facility design with your vaccine platform roadmap. Whether you are constructing a greenfield standalone vaccine campus or retrofitting an existing animal biologics site for expanded licensed production, our turnkey GMP engineering solution establishes a robust, inspection-ready manufacturing foundation that balances biosecurity, product quality, operational throughput and long-term regulatory sustainability.
